1 Fineman M, Flanagan S, Taylor K, et al. Pharmacokinetics and  pharmacodynamics of exenatide extended-release after single and multiple dosing. Clin Pharmacokinet 2011; 50: 65–74.  2 Drucker DJ, Buse JB, Taylor K, et al. Exenatide once weekly versus  twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study. Lancet 2008; 372: 1240–50.  3 Bergenstal RM, Wysham C, MacConell L, et al. Eﬃ   cacy and safety  of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial. Lancet 2010; 376: 431–39.  4 Diamant M, Van Gaal L, Stranks S, et al. Once weekly exenatide  compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial. Lancet 2010; 375: 2234–43.  5 Russell-Jones D, Cuddihy RM, Hanefeld M, et al. Eﬃ   cacy and safety